BioSpace News Archive

Amgen (NASDAQ:AMGN) will present at the 2022 Jefferies Healthcare Conference at 9:30 a.m. ET on Wednesday, June 8, 2022.

Blueprint Medicines Corporation announced that, effective on June 1, 2022, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 47,587 shares of its common stock and an aggregate of 23,787 restricted stock units to twenty-seven new employees under Blueprint Medicines’ 2020 Inducement Plan.

TransMedics Group, Inc. announced that on June 1, 2022, TransMedics granted non-qualified stock options to purchase an aggregate of 35,000 shares of its common stock to three employees as a material inducement for each employee’s entry into employment with TransMedics.

Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, announced the grant of restricted stock unit awards for an aggregate of 77,850 shares of Syros common stock to four newly hired employees in connection with their commencement of employment with Syros.

Atara Biotherapeutics, Inc. reported the grant of an aggregate of 126,928 restricted stock units of Atara’s common stock to four newly hired employees and stock options to purchase an aggregate of 186,378 shares of Atara’s common stock to three such newly hired employees.

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to 11 new employees.

Kite, a Gilead Company (Nasdaq: GILD), today announced findings from a safety and efficacy retrospective analysis by race and ethnicity from the ongoing post-authorization study of Yescarta® (axicabtagene ciloleucel) in adult patients with relapsed or refractory large B-cell lymphoma (LBCL).

Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 24,000 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 64,900 shares of Arcutis’ common stock to seven newly hired employees.

Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, announced it granted inducement awards on May 31, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to four individuals hired by Adicet in May 2022.

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced that senior management will be participating in multiple upcoming institutional investor conferences.